CBD May Boost Chemotherapy Effectiveness Against Aggressive Brain Cancer, Finds Study
A new study published by Pharmaceutics finds that the cannabis compound cannabidiol, better known as CBD, could enhance the effectiveness of certain chemotherapy drugs against glioblastoma multiforme, one of the most aggressive and difficult-to-treat forms of brain cancer. The research was conducted by scientists from Complutense University of Madrid and Universidad San Pablo-CEU, who set out to evaluate whether CBD could be paired with existing cancer drugs in a way that improves their anticancer effects while maintaining chemical stability.
Using two human glioblastoma cell lines, the researchers first tested CBD on its own and found that it significantly reduced cancer cell viability and limited cell migration, a key factor in tumor spread. They then evaluated CBD in combination with several common chemotherapeutic agents, including temozolomide and carmustine. Among all combinations tested, only CBD paired with paclitaxel demonstrated both favorable chemical compatibility and additive or synergistic anticancer effects.
The enhanced impact of the CBD–paclitaxel combination was confirmed in additional laboratory models, including an in ovo system that allowed researchers to observe tumor behavior in a living biological environment. The combination also continued to show an ability to slow cancer cell migration, reinforcing its potential therapeutic value.
To improve delivery, the team engineered two lipid nanocapsule formulations designed to carry both CBD and paclitaxel. One formulation was intended for direct brain administration, while the other was optimized for systemic use. Both maintained a consistent CBD-to-paclitaxel ratio and showed physical stability suitable for further development.
The authors conclude that CBD and paclitaxel co-loaded lipid nanocapsules could represent a flexible and promising nanomedicine platform for future glioblastoma treatments, warranting additional preclinical and clinical investigation.